Abstract: Phthalocyanines of the formula (I) where the symbols and indices each have the definitions specified in the description are suitable as markers for liquids, especially mineral oils.

Abstract: The present invention relates to a compound of formula (II) chosen from (IIa) and (IIb) or of formula (VI) chosen from (VIa) and (VIb) of following general formulae: in which: X1, X2, X3, X4 and X5 represent, independently of one another, L-Y in which L represents a C1-C3 alkyl group, preferably (CH2), with n=1 to 3, Y represents —CONH2, —CO—NR7R8 or —NR7-CO—R8, or an isomer, an enantiomer or a diastereoisomer of these or their mixtures or a pharmaceutically acceptable salt of the compounds of formulae (VIa) and (VIb). It also relates to a complex of these compounds with a paramagnetic metal or a radionuclide and their use in diagnostic methods.

Abstract: Compositions comprising motexafin gadolinium, as well as methods for using these compositions in the treatment of brain metastases, are described herein.

Abstract: A rare-earth fluorescent complex which forms a fluorescent complex with two or more rare-earth metals such as europium and terbium and can effectively be excited at a wavelength of 340 nm or longer; a fluorescent labeling agent comprising the rare-earth fluorescent complex; a method of fluorescent labeling in which the rare-earth fluorescent complex is used as a labeling agent; and a method of fluorometric analysis in which the fluorescent labeling agent is used. The rare-earth fluorescent complex is characterized by having a cyclic ligand comprising a 4-biphenyl-2,2?:6?,2?-terpyridine skeleton and a 2,6-bis(3?-aminomethyl-1?-pyrazolyl)pyrazine skeleton bonded thereto.

Abstract: This invention relates to novel diaza-bicyclo-alkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Abstract: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a composition may be administered to a subject to control bone resorption, inflammation, and/or pain.

Abstract: A process for producing compound 1,4,7,10,13,16,21,24-octaazabicyclo[8.8.8]hexacosa, 4,6,13,15,21,23-hexaene (2) and then compound 1,4,7,10,13,16,21,24-octaazabicyclo[8.8.8]hexacosane (1) from compound (2) is described. The process uses a reaction between triaminoethylamine and glyoxal in the presence of water, alcohol and tertiary amine at low temperature to produce compound 2. Then compound 1 is produced from compound 2 by reduction with an alkali metal containing ammonia as the reductant. The compounds are aza cryptands which are used to bind metals and the like for electrides, and in alkalides, medicine and water treatment, for instance.

Abstract: Hard surface cleaning agents comprising a macrocyclic compound of the general formula L: wherein each of n1, n2 and n3 independently represents 1 or 2; and hard surface cleaning agents comprising a transition metal complex of the general formula (I): [MLaXb]cY??(1) wherein M represents a metal selected from the group consisting of manganese, iron, cobalt, copper, ruthenium, molybdenum, and combinations thereof; X represent a neutral or anionic ligand; Y represents a non-complex-bound anion; a represents 1 or 2; each of b and c independently represents a number of 0 to 6, with the proviso that b and c are selected such that the complex is neutral based on M, X and Y; and L represents a macrocyclic ligand of the general formula L; and methods of cleaning hard surfaces therewith.

Abstract: A multidentate ligand includes at least two planar tetradentate coordination sites in one plane, each of the planar tetradentate coordination sites containing four nitrogen-containing groups of at least one of imino, amido and amino groups, and has the nitrogen atoms of the four nitrogen-containing groups as coordinating atoms in one plane. A metal complex assembly has one of two-dimensional and three-dimensional structures and contains metal complex chains and electroconductive wires, the metal complex chains each contain assembled metal complexes, the electroconductive wires each contain molecules serving as at least one of an acceptor and a donor, and the metal complex chains intersect with the electroconductive wires at such positions that the metal complexes and the molecules serving as at least one of an acceptor and a donor are capable of interacting with each other.

Abstract: The present invention relates to the preparation and pharmacological use of sinomenine derivatives of formula I. The approach disclosed herein is the modification of D ring by-substituting for R. Additional substitutions in the other rings are also provided herein. Several of the sinomenine derivatives have significantly greater anti-inflammation activity when compared with the parent compound.

Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.

Abstract: The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities.

Abstract: A phthalocyanine compound of formula (I) is provided for use in a recording layer of an optical recording media. In formula (I), M1 is a divalent transition metal, or two hydrogen atoms; X is halogen; Y is —OR1; R1 is alkyl which is unsubstituted or substituted by halogen, halogen, hydroxyl, alkoxy, alkylamino; R2 is R3 and R4 independently denote H, halogen, alkyl and alkoxyl; R5 is unsubstituted or substituted phenyl, benzyl, nathalenyl, or heterocycle; E denotes a single bond, C1-C4 alkyl, R6—C—O—C(?O), R6—O—C(?O)— or R6—S—C(?O)—; R6 is unsubstituted or substituted phenyl, benzyl, nathalenyl, heterocycle or C1-C4 alkyl; x is a number from 0 to 8; y is a number from 0 to 8; z is a number from 0 to 4; and M2 is a divalent transition metal.

Abstract: Phthalocyanine dyes of general formula (II) and, in particular, of general formula (III) wherein R1-R8, R9-R12, Me, M, m, n , o and p are as defined in the specification, are excellent dyes for dying and printing cellulose containing materials and textile materials, and, especially, for the preparation of inks for ink jet printing.

Abstract: The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

Abstract: A crystalline (9S-(9?,10?,12?))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3?,2?,1?-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one hydrate and ways to make it are disclosed.

Abstract: A crystalline (9S-(9?,10?,12?))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(methoxycarbonyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3?,2?,1?-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one bis(N,N?-dimethylformamidate) and ways to make it are disclosed.

Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.

Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

Abstract: A dimer of phenazine-1-carboyxlic acid natural products from fluorescent pseudomonad bacterium and a method of preparing a dimer of phenazine-1-carboxylic acid natural product are disclosed herein. The method comprises growing the bacterium in a water based liquid medium under favorable pH and temperature with continuous agitation, extracting the dimer of phenazine-1-carboyxlic acid natural product from the medium by centrifugation using organic solvents, filtering the resultant emulsion to separate the aqueous layer in a separation funnel, isolating the crude dimer of phenazine-1-carboyxlic acid natural product from the organic layer by evaporating the organic solvent, and purifying the dimer of phenazine-1-carboxylic acid natural product by chromatography.

Abstract: An IR-absorbing phthalocyanine dye suitable for formulation in a solvent-based or oil-based ink vehicle is disclosed. The phthalocyanine comprises one or more sulfonate groups and a counterion of at least one sulfonate group is a phosphonium cation. Phosphonium salts of sulfonated gallium naphthalocyanines exemplify such dyes.

Abstract: The present invention relates to compounds of formula wherein X is —S— or —NH—; R3/R4 together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR2, —CONR2, —CO-lower alkyl or benzyl; or R3/R4 form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; and R, R1, R2, and R5 are as defined herein and to pharmaceutically suitable acid addition salts thereof.

Abstract: Cucurbit[n]uril compounds each containing phthalhydrazide units in a macrocycle wall thereof, which compound is selected from the group consisting of CB[5], CB[6], CB[7] and CB[8] compounds, the compounds having an internal cavity which may be used to contain a guest compound.

Abstract: Macrocyclic pyrimidine derivatives of general formula I in which R1 to R5, X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.

Abstract: This invention is directed to pyridine-containing macroheterocyclic compounds useful as kinase inhibitors, methods for producing such compounds and methods for treating or preventing a kinase mediated disorder.

Abstract: This invention relates to novel diazabicyclic biaryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Abstract: This invention relates to novel 1,4-diazabicycloalkane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Abstract: Uses of cucurbituril derivatives are disclosed.

Abstract: The present invention relates to a complex composed of cucurbituril and fullerene and a method for manufacturing the complex on a solid-phase. A complex in accordance with the present invention can be usefully used as a medicine delivery means in the field of pharmaceutics.

Abstract: The instant invention relates to stable free nitroxyl radicals of formula (I) wherein at least one of the substituents R is —O. and the others are hydrogen or OH; X is —NR1R2, wherein R1 and R2 are independently hydrogen, C1–C18alkyl or together with the nitrogen atom to which they are bound form a 5 or 6 membered ring which may be further interrupted by an O atom. Further subjects of the invention are an oxidation process for alcohols to aldehydes or ketones or to carboxylic acids in the presence of a compound of formula (I) and the use of stable free nitroxyl radicals of formula (I) as oxidation catalysts.

Abstract: The present invention provides certain non-symmetric tripyrranes; that is, tripyrranes that do not contain a mirror plane of symmetry perpendicular to the plane containing the tripyrrane. Further, the invention includes texaphyrin compounds and sapphyrin compounds, as well as other polypyrrolic macrocycles, prepared using tripyrranes of Formula I as a precursor. These macrocycles are characterized by a tripyrrolic portion of the macrocyclic ring having substituents that cause the heterocycle to lack a plane of symmetry perpendicular to the plane of the macrocycle.

Abstract: Injectible formulations comprising motexafin gadolinium are described herein.

Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted. The invention also relates to novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching caused by the measuring medium.

Abstract: Improved ?,??-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin compounds are provided as photosensitizers. Pharmaceutical compositions and photodynamic therapy comprising them are also disclosed.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided: where R1 through R7 are defined herein. The compounds of formula (I) are 5HT2c agonists or partial agonists, and are useful for treating a variety of disorders.

Abstract: A method of making chlorins comprises the steps of reacting (e.g. condensing) a dipyrrin western half intermediate with an eastern half intermediate to form a tetrahydrobilene, and then cyclizing the tetrahydrobilene to form a chlorin. Intermediates including tetrahydrobilenes useful in such reactions are also described.

Abstract: Novel macrocyclic compounds are constructed to include large cyclic structures that are interrupted by at least one ring system. Each interrupting ring system includes two bridgehead atoms. Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical functional groups. The ring systems can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring. These can also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the macrocyclic compounds. In accordance with certain embodiments of the invention, libraries of such macrocyclic compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the library.

Abstract: Formulation components such as bleach boosting compounds selected from the group consisting of bleach boosters comprising quaternary imine cations, zwitterions, polyions having a net charge of from about +3 to about 3 and mixtures thereof, bleaching species comprising oxariridinium cations, zwitterions, polyions having a net charge of from about +3 to about ?3 and mixtures thereof, and mixtures thereof are disclosed. The bleach boosting compounds increase bleaching effectiveness even in lower temperature solutions and provides improved stability toward unwanted boosting compound decomposition. The bleach boosting compounds are ideally suited for inclusion into bleaching compositions including those with detersive surfactants and enzymes. Also provided is a method for laundering a fabric employing the bleach compounds, a laundry additive product employing the bleach boosting compounds.

Abstract: The present invention provides compounds of Formula (I): wherein: R1, R2, R3, R4, R5, R6 R7, R8, n, m, and X have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods as well as processes and intermediates useful for preparing compounds of Formula (I). The compounds are 5-HT ligands and are useful for treating diseases wherein modulation of 5-HT activity is desired.

Abstract: Compounds of Formula I: wherein A and B are linking groups; R1, R2, R3 and R4 are defined moieties. An exemplary compound is: These compounds function as potassium channel blocking agents, and can be used in a wide variety of pharmaceutical compositions for the treatment of a wide variety of diseases.

Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Abstract: This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

Abstract: The radiation sensitization potential of a candidate compound can be screened by determine its ability to generate one or more reactive oxygen species under appropriate conditions. Compounds determined to have radiation sensitization potential are employed in methods for treating atheroma, tumors and other neoplastic tissue as well as other conditions that typically responsive to radiation sensitization.

Abstract: Novel meso-aryl substituted expanded porphyrins comprising of alternate arrangement of more than six of pyrrole units bridged by a methine group whose hydrogen is substituted with Ar-group; and their synthetic method. Ar-group is either a 2,6-substituted phenyl group which can possess a substituent at the other 3, 4, and 5 positions, or 9-anthryl group which can possess a substituent at the other positions of the anthracence, or a cyclohexyl group which can possess a substituent at the other positions of the cyclohexyl group. The substituents at the 2 and 6 positions mentioned above can be selected independently from halogen atom or lower alkyl group of carbon number 1 to 4, substituents at 3-5 positions, 9-anthryl group and cyclohexyl group can be selected independently from the group consisting of substituted or non-substituted alkyl of carbon number 5 or 6, substituted or non-substituted aryl group, besides above mentioned substituents at 2 and 6 positions. Each Ar-group can be different.

Abstract: A method of manufacturing substance GM-95 having general formula [I], comprising (a) deprotecting a macrocyclic compound having general formula [II] (wherein, R1's are the same or different and each represents a lower alkyl group, and R2 represents a thiol protecting group) by removing acetal protecting groups (the R1's) thereof, and forming an oxazole ring through an intramolecular cyclization reaction between produced formyl group and an amide group, and (b) deprotecting a resulting macrocyclic compound having general formula [III] (wherein, R2 is as mentioned above) by removing the thiol protecting group (R2) thereof, and forming a thiazoline ring through an intramolecular cyclization reaction between a thiol group thus produced and an amide group.

Abstract: A microorganism capable of producing substances K97-0239 comprising K97-0239A represented by the following formula [I]: and K97-0239B represented by the following formula [II]: is cultured in a medium and the substances K97-0239 thus accumulated in the medium are collected from the culture medium. The obtained substances have a low toxicity and specifically inhibit the foaming of macrophages. Owing to these characteristics, they are useful in preventing and treating human arteriosclerosis and diseases caused thereby.

Abstract: Macrocyclic pyrimidine derivatives of general formula I 1

Abstract: Corroles of formula I, wherein Ar is aryl or heteroaryl; M is absent or is a metal selected from Al, Ga, Co, Mn, Fe, Ru, Sn, Cr or Rh; E2, E3 and E17, the same or different, each is H, SO2Cl, SO3H, SO2NR1R2, CO2H, CO2R, COC1, CONR1R2, CHO or NO2, R is alkyl or aryl, and R1 and R2, the same or different, each is H, alkyl, aryl or together with the N atom to which they are attached form a saturated 5-6 membered ring optionally containing a further heteroatom selected from O, S and N; and E18 is H or CHO; or E3 and E18 are H and E2 and E17 are each SO2, both SO2 groups being linked by a bridge R3N(R4)-phenyl-(R4)NR3, wherein R3 is H, alkyl, phenyl or aralkyl, and R4 is alkylene; and provided that at least one of E2, E3, E17 and E18 is not H, are provided. The corroles can be used for tumor detection and treatment, in photovoltaic devices, as catalysts and as intermediates.

Abstract: The present invention relates to a complex composed of cucurbituril and fullerene and a method for manufacturing the complex on a solid-phase.